Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03773107 · OUTCOME

Progression-free Survival (PFS)

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma · Source last updated 2025-01-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Inter-Quartile Range
Time frame
approx. 5 years

What was measured

PFS is defined as the duration of time from the initiation of study treatment with ruxolitinib to first occurrence of either progressive disease or death without progressive disease.

Analysis population: All participants who initiate study treatment.

Groups in this outcome

Phase I 5mg Ruxolitinib

Cohort 1) 5mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Phase I 10mg Ruxolitinib

Cohort 2) 10mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Phase I 15mg Ruxolitinib

Cohort 3) 15mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase I 5mg Ruxolitinib5
Phase I 10mg Ruxolitinib4
Phase I 15mg Ruxolitinib3

Reported measurements

Source class 1
Values in months · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
Phase I 5mg Ruxolitinib3.0Not reported1.83.2Not reported
Phase I 10mg Ruxolitinib6.1Not reported2.68.3Not reported
Phase I 15mg Ruxolitinib10.6Not reported1.310.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.8
        upper Limit
        3.2
        value
        3.0
      2. group Id
        OG001
        lower Limit
        2.6
        upper Limit
        8.3
        value
        6.1
      3. group Id
        OG002
        lower Limit
        1.3
        upper Limit
        10.6
        value
        10.6
denoms
  1. counts
    1. group Id
      OG000
      value
      5
    2. group Id
      OG001
      value
      4
    3. group Id
      OG002
      value
      3
    units
    Participants
description
PFS is defined as the duration of time from the initiation of study treatment with ruxolitinib to first occurrence of either progressive disease or death without progressive disease.
dispersion Type
Inter-Quartile Range
groups
  1. description
    Cohort 1) 5mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
    id
    OG000
    title
    Phase I 5mg Ruxolitinib
  2. description
    Cohort 2) 10mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
    id
    OG001
    title
    Phase I 10mg Ruxolitinib
  3. description
    Cohort 3) 15mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
    id
    OG002
    title
    Phase I 15mg Ruxolitinib
param Type
MEDIAN
population Description
All participants who initiate study treatment.
reporting Status
POSTED
time Frame
approx. 5 years
title
Progression-free Survival (PFS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice